Clinical trial Recruiting at 2 sites Interventional Ages 18 to 60

How remifentanil changes propofol-induced burst suppression.

Official title: Influence of Variable Plasma Concentrations of Remifentanil on Burst Suppression (BS) Event Rate in Electroencephalographic (EEG) Recordings of Human Subjects Undergoing Total Intravenous General Anesthesia (TIVA) Under Propofol

Run by University of Chile · NCT06237101 · Data updated 2026-11-12

We will test whether different doses of remifentanil change the propofol concentration needed to produce burst suppression in adults (18–60) having elective surgery.

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment20 (estimated)
SponsorUniversity of Chile
Academic / other
Locations2 sites (Santiago, RM and 1 other locations)
StatusRecruiting
StartedMarch 1, 2024
Main results expectedAugust 31, 2026
Study endsSeptember 30, 2026
Registry record updatedNovember 20, 2025
Trial IDNCT06237101 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–60 with ASA physical status I or II scheduled for low- or intermediate-risk elective surgery who are free of neurologic/psychiatric disease and not taking psychoactive drugs or opioids.

Probably not a fit

Patients with neurologic or psychiatric disorders, altered baseline consciousness, significant organ dysfunction, BMI over 35, current opioid or psychoactive drug use, or propofol allergy are excluded and would not benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adult patients (ASA I–II) undergoing low- or intermediate-risk elective surgery receive sequential remifentanil and propofol while frontal EEG is recorded. After loss of consciousness, patients are randomized to a medium or high remifentanil effect-site concentration and propofol infusion rates are adjusted to determine the concentration that produces burst suppression. Burst suppression thresholds (propofol concentrations) are compared between the remifentanil dose groups. Routine monitoring and neuromuscular blockade are used to facilitate standardized airway management and surgical conditions.

Why it matters

Potential benefit: If successful, this could help anesthesiologists tailor anesthetic dosing to reduce unnecessary propofol exposure while maintaining appropriate EEG suppression.

How similar studies have gone: Prior work has shown that opioids can modify EEG patterns and interact with propofol, but direct randomized data specifically testing remifentanil's facilitation of propofol-induced burst suppression are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* American Society of Anesthesiology I or II
* Elective surgery of low or intermediate risk

Exclusion Criteria:

* Neurological disease
* Psychiatric disease
* Use of psychoactive drugs or opioids
* Altered basal state of consciousness
* Allergy to propofol
* Body mass index \> 35 kg/m2
* Pre-existing renal, cardiac and/or hepatic dysfunction
* Patient's refusal to participate

Where it's running

  • Centro de Investigación Cínica Avanzada (CICA), Hospital Clinico de la Universidad de Chile
    Santiago, Rm, Chile
    Recruiting
  • Hospital Clinico de la Universidad de Chile
    Santiago, Rm, Chile
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.